Trial Profile

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Dec 2025 Actual primary completion date changed from 1 Oct 2017 to 25 Oct 2017.
23 Dec 2025 Status changed from active, no longer recruiting to completed.
14 Nov 2023 Results assessing the association between ballooning reduction and steatosis reduction in the resmetirom versus placebo group using second harmonic generation (SHG)/two-photon excited fluorescence (TPEF) microscopy imaging of paired biopsy samples with artificial intelligence (AI)-based algorithms presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com